Erratum: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Neuroblastoma remains a major cause of cancer-linked mortality in children. miR-204 has been used in microRNA expression signatures predictive of neuroblastoma patient survival. The aim of this study was to explore the independent association of miR-204 with survival in a neuroblastoma cohort, and to investigate the phenotypic effects mediated by miR-204 expression in neuroblastoma. METHODS: Neuroblastoma cell lines were transiently transfected with miR-204 mimics and assessed for cell viability using MTS assays. Apoptosis levels in cell lines were evaluated by FACS analysis of Annexin V-/propidium iodide-stained cells transfected with miR-204 mimics and treated with chemotherapy drug or vehicle control. Potential targets of miR-204 were validated using luciferase reporter assays. RESULTS: miR-204 expression in primary neuroblastoma tumours was predictive of patient event-free and overall survival, independent of established known risk factors. Ectopic miR-204 expression significantly increased sensitivity to cisplatin and etoposide in vitro. miR-204 direct targeting of the 3' UTR of BCL2 and NTRK2 (TrkB) was confirmed. CONCLUSION: miR-204 is a novel predictor of outcome in neuroblastoma, functioning, at least in part, through increasing sensitivity to cisplatin by direct targeting and downregulation of anti-apoptotic BCL2. miR-204 also targets full-length NTRK2, a potent oncogene involved with chemotherapy drug resistance in neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
miR-204 is required for lens and retinal development via Meis2 targeting
Conte, I., Carrella, S., Avellino, R., Karali, M., Marco-Ferreres, R., Bovolenta, P., & Banfi, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914785107 · Cited by 181
Cited by
The return of the nucleus: transcriptional and epigenetic control of autophagy
Füllgrabe, J., Klionsky, D. J., & Joseph, B. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3716 · Cited by 466
Genetic regulation of human adipose microRNA expression and its consequences for metabolic traits
Civelek, M., Hagopian, R., Pan, C., Che, N., Yang, W.-P., Kayne, P. S., Saleem, N. K., Cederberg, H., Kuusisto, J., Gargalovic, P. S., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt159 · Cited by 89
Casinelli, G., LaRosa, J., Sharma, M., Cherok, E., Banerjee, S., Branca, M., Edmunds, L., Wang, Y., Sims-Lucas, S., Churley, L., et al. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.82 · Cited by 52
Chen, B., Duan, L., Yin, G., Tan, J., & Jiang, X. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000092 · Cited by 51
Metadata
- Authors
- Ryan, J., Tivnan, A., Fay, J., Bryan, K., Meehan, M., Creevey, L., Lynch, J., Bray, I. M., O'Meara, A., Tracey, L., Davidoff, A. M., & Stallings, R. L.
- Venue
- British Journal of Cancer
- Published
- 2012-09
- Volume
- 107
- Issue
- 7
- Pages
- 1203-1203
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2080162017
- Cited by
- 94
- References
- 2
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Erratum: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. https://app.cochat.ai/papers/10.1038/bjc.2012.425
- The paper
- Ryan, J., Tivnan, A., Fay, J., Bryan, K., Meehan, M., Creevey, L., Lynch, J., Bray, I. M., O'Meara, A., Tracey, L., Davidoff, A. M., & Stallings, R. L. (2012). Erratum: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. British Journal of Cancer. https://doi.org/10.1038/bjc.2012.425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.